[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20121158A1 - Derivados de feniletinilo como moduladores alostericos positivos (map) - Google Patents

Derivados de feniletinilo como moduladores alostericos positivos (map)

Info

Publication number
PE20121158A1
PE20121158A1 PE2012000562A PE2012000562A PE20121158A1 PE 20121158 A1 PE20121158 A1 PE 20121158A1 PE 2012000562 A PE2012000562 A PE 2012000562A PE 2012000562 A PE2012000562 A PE 2012000562A PE 20121158 A1 PE20121158 A1 PE 20121158A1
Authority
PE
Peru
Prior art keywords
phenyletinyl
alkyl
map
pyrimidin
amine
Prior art date
Application number
PE2012000562A
Other languages
English (en)
Inventor
Luke Green
Wolfgang Guba
Georg Jaeschke
Synese Jolidon
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20121158A1 publication Critical patent/PE20121158A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO DE FENILETINILO DE FORMULA (I), DONDE R1 ES H, HALOGENO, ALQUILO C1-C4 O ALQUILO C1-C4 SUSTITUIDO POR HALOGENO; R2 ES H, ALQUILO C1-C4, =O, ALCOXI C1-C4, FENILO, ENTRE OTROS; X ES N, CF O CH; L ES NR3, O, NHC(R3)2, ENTRE OTROS; R3 ES H O ALQULIO C1-C4; cic ES TETRAHIDROPIRANO-2,3-ILO, OXETAN-3-ILO, PIRAZOLIDINILO, MORFOLINILO, ENTRE OTROS; n ES 1, 2 O 3. SON COMPUESTOS PREFERIDOS: rac-(2,2-DIMETIL-TETRAHIDRO-PIRANO-4-IL)-(5-FENILETINIL-PIRIMIDIN-2-IL)-AMINA, rac-7-OXA-BICICLO[2,2,1]HEPT-2-IL-(5-FENILETINIL-PIRIMIDIN-2-IL)-AMINA, (3-METIL-OXETAN-3-ILMETIL)-(5-FENILETINIL-PIRIMIDIN-2-IL)-AMINA, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS POSITIVOS (MAP) DEL RECEPTOR DE GLUTAMATO METABOTROPICO SUBTIPO 5 (mGluR5) Y SON UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA Y ENFERMEDADES COGNITIVAS
PE2012000562A 2009-10-27 2010-10-25 Derivados de feniletinilo como moduladores alostericos positivos (map) PE20121158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09174136 2009-10-27

Publications (1)

Publication Number Publication Date
PE20121158A1 true PE20121158A1 (es) 2012-08-27

Family

ID=43598346

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000562A PE20121158A1 (es) 2009-10-27 2010-10-25 Derivados de feniletinilo como moduladores alostericos positivos (map)

Country Status (19)

Country Link
US (2) US8389536B2 (es)
EP (1) EP2493856B1 (es)
JP (1) JP5463420B2 (es)
KR (1) KR101385363B1 (es)
CN (1) CN102596909B (es)
AR (1) AR078756A1 (es)
AU (1) AU2010311624B2 (es)
BR (1) BR112012009732A2 (es)
CA (1) CA2778219C (es)
CL (1) CL2012001072A1 (es)
ES (1) ES2579435T3 (es)
HK (1) HK1171743A1 (es)
IL (1) IL219110A (es)
MX (1) MX2012004963A (es)
PE (1) PE20121158A1 (es)
RU (1) RU2561920C2 (es)
TW (1) TWI410415B (es)
WO (1) WO2011051201A1 (es)
ZA (1) ZA201203053B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012031298A2 (en) 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
US8691821B2 (en) 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) * 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
AU2013333984B2 (en) * 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
CN104603110B (zh) * 2012-10-18 2016-08-31 霍夫曼-拉罗奇有限公司 作为mGluR5受体活性的调节剂的乙炔基衍生物
ES2599553T3 (es) * 2012-10-18 2017-02-02 F. Hoffmann-La Roche Ag Derivados de etinilo como moduladores de la actividad del receptor mGluR5
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
CA2921427A1 (en) 2013-08-16 2015-02-19 Duke University Substituted hydroxamic acid compounds
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
WO2015024016A2 (en) 2013-08-16 2015-02-19 Duke University 2-piperidinyl substituted n,3-dihydroxybutanamides
SI3303316T1 (sl) 2015-06-03 2020-07-31 F. Hoffmann-La Roche Ag Derivati etinila
DK3322701T3 (da) 2015-07-15 2019-07-08 H Hoffmann La Roche Ag Ethynylderivater som metabotropiske glutamatreceptormodulatorer
KR20190026805A (ko) 2016-07-18 2019-03-13 에프. 호프만-라 로슈 아게 에틴일 유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063741B (en) 2001-02-23 2006-02-10 Merck & Co Inc Nonaryl-Heterocyclic NMDA/NR2B Antagonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0512844D0 (en) * 2005-06-23 2005-08-03 Novartis Ag Organic compounds
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
AU2008259776A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
WO2009098208A1 (en) 2008-02-05 2009-08-13 Neurosearch A/S Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
AR078756A1 (es) 2011-11-30
EP2493856A1 (en) 2012-09-05
ES2579435T3 (es) 2016-08-11
US20110098313A1 (en) 2011-04-28
CL2012001072A1 (es) 2012-09-14
BR112012009732A2 (pt) 2021-09-21
AU2010311624A1 (en) 2012-06-07
CA2778219C (en) 2017-10-31
US20130131056A1 (en) 2013-05-23
HK1171743A1 (en) 2013-04-05
JP5463420B2 (ja) 2014-04-09
US8716316B2 (en) 2014-05-06
JP2013508434A (ja) 2013-03-07
KR20120067373A (ko) 2012-06-25
AU2010311624B2 (en) 2015-09-03
RU2561920C2 (ru) 2015-09-10
KR101385363B1 (ko) 2014-04-14
CA2778219A1 (en) 2011-05-05
IL219110A0 (en) 2012-06-28
TWI410415B (zh) 2013-10-01
MX2012004963A (es) 2012-06-12
TW201121951A (en) 2011-07-01
IL219110A (en) 2015-03-31
EP2493856B1 (en) 2016-04-27
ZA201203053B (en) 2013-01-30
US8389536B2 (en) 2013-03-05
RU2012120307A (ru) 2013-12-10
WO2011051201A1 (en) 2011-05-05
CN102596909B (zh) 2014-09-03
CN102596909A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20130155A1 (es) Derivados de ariletinilo
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20120110A1 (es) [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
PE20141283A1 (es) Nuevos derivados biciclicos de dihidroisoquinolin-1-ona
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
CU24083B1 (es) Derivados de oxazina útiles como inhibidores de bace para el tratamiento de trastornos neurológicos
CR10236A (es) Modulares del indol sulfonamida de receptores de progesterona
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20081612A1 (es) Analogos de las pterinas
PE20191156A1 (es) Nuevos derivados de isoxazolil eter como pam de gabaa alfa5
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
PE20110061A1 (es) Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed